GHB slows brain activity by activating the same receptors targeted by your brain’s main inhibitory signaling system. At low doses, this produces relaxation and mild euphoria. At higher doses, it suppresses consciousness, breathing rate, and protective reflexes. The effects come on fast and clear the body quickly, with an elimination half-life of roughly 40 minutes, but the neurological consequences of misuse can be severe and, in overdose, fatal.
How GHB Interacts With Brain Receptors
Your brain actually produces tiny amounts of GHB on its own, at concentrations of about 2 to 20 nanomoles per gram of brain tissue. At those natural levels, GHB binds to a dedicated “GHB receptor” with high affinity. But when someone takes GHB as a drug, blood and brain concentrations climb far beyond anything the body produces naturally, and a different receptor takes center stage.
At the concentrations reached by a recreational or clinical dose, GHB acts primarily on GABA-B receptors, the same targets activated by the neurotransmitter GABA (your brain’s chief “slow down” chemical). Activating GABA-B receptors triggers a cascade: neurons become less excitable, release fewer stimulating signals, and shift the brain toward sedation. This GABA-B activation is responsible for virtually all of GHB’s major effects, from sleepiness to respiratory depression.
What Changes at Different Doses
GHB’s effects on the brain are sharply dose-dependent, which is part of what makes it dangerous. The margin between a dose that produces euphoria and one that causes a medical emergency is narrow.
- Low doses (around 10 mg/kg): Mild sedation, reduced anxiety, and amnesia. At this level, GHB inhibits dopamine release, which may contribute to a calm, relaxed state.
- Moderate doses (20 to 30 mg/kg): Deeper sedation with cycles of REM sleep. Users may feel strong euphoria before losing consciousness.
- High doses (50 mg/kg and above): Slowed heart rate, respiratory depression, and coma. These effects can be fatal.
One of GHB’s more unusual features is a biphasic effect on dopamine. Low doses suppress dopamine release, while high doses actually promote it. This flip may help explain why users sometimes report a burst of euphoria or stimulation before the sedative effects take over.
How GHB Suppresses Consciousness
The thalamus is the brain’s relay station, filtering sensory information on its way to the cortex. GHB disrupts this relay in a lopsided way. At concentrations associated with absence-seizure-like brain waves, GHB blocks about 96% of the excitatory (glutamate-driven) signals arriving from the cortex to the thalamus, while only reducing about 43% of the inhibitory signals in the same circuit. This imbalance tips thalamic neurons into slow, rhythmic oscillation patterns similar to those seen in deep sleep and absence seizures.
At even higher concentrations, both excitatory and inhibitory inputs are dampened so heavily that thalamic neurons shift into a strongly hyperpolarized state associated with progressively decreasing alertness. Combined with similar dampening in cortical neurons, this accounts for the deep sedation and, at clinical doses, the normalization of disrupted sleep patterns that makes GHB useful in treating narcolepsy.
Effects on Sleep Architecture
GHB has a pronounced effect on sleep stages, which is why a pharmaceutical form (sodium oxybate) is prescribed for narcolepsy. In clinical trials, patients taking 9 grams nightly in two divided doses saw a median increase of 52.5 minutes of deep slow-wave sleep (stages 3 and 4) after eight weeks. At the same time, light stage 1 sleep decreased, the number of nighttime awakenings dropped significantly, and total sleep time increased.
REM sleep showed a modest overall decrease at higher doses but was not dramatically altered. The net result is a more consolidated, deeper night of sleep with fewer interruptions. For people with narcolepsy, whose sleep is severely fragmented, this consolidation reduces daytime sleepiness and cataplexy episodes. Outside a clinical setting, though, the same mechanism means that someone who takes GHB recreationally can fall into a sleep so deep they cannot be roused, which is one reason it is implicated in drug-facilitated assaults.
Why Overdose Is Life-Threatening
Respiratory depression is the primary way GHB kills. The mechanism is straightforward: GHB activation of GABA-B receptors in the brainstem slows breathing rate in a dose-dependent fashion. The body tries to compensate by increasing the depth of each breath (tidal volume), so total air exchange stays relatively stable for a while. But once breathing rate drops low enough, tidal volume hits a physiological ceiling and can no longer compensate. At that point, total ventilation falls steeply, and without intervention, the result is fatal respiratory failure.
Research in animal models has confirmed that blocking GABA-B receptors completely prevents GHB’s effect on breathing rate, while blocking GABA-A receptors has no meaningful effect. This tells us the respiratory danger is driven almost entirely through a single receptor pathway, which is useful for developing treatments but does nothing to protect someone who has already taken too much.
Combining GHB with alcohol or other sedatives is especially dangerous because those substances also depress breathing through overlapping pathways, pushing total ventilation past the point of no return at lower GHB doses than would otherwise be lethal.
Long-Term Brain Effects
Occasional GHB use, on its own, has not been clearly linked to structural brain damage in imaging studies. Researchers comparing regular GHB users who had never experienced a GHB-induced coma to non-users found no significant differences in brain structure or self-reported impulsivity.
The picture changes when repeated GHB-induced comas enter the equation. Users who had experienced multiple comas showed measurable microstructural changes in white matter, specifically higher fractional anisotropy in the body of the corpus callosum (the main bridge between brain hemispheres) and changes in frontal white matter tracts. These same individuals reported higher impulsivity, and the degree of impulsivity correlated with alterations in white matter tracts involved in impulse control. Functional imaging studies have also linked repeated GHB comas to abnormal activation in the prefrontal cortex and hippocampus, along with disrupted connectivity between brain networks responsible for executive function and the default mode network (the brain’s “idle” circuit).
A related piece of evidence comes from a rare genetic condition in which the enzyme that breaks down GHB is missing, causing GHB and GABA to accumulate chronically. People with this condition show gray matter shrinkage and white matter abnormalities in the prefrontal cortex, hippocampus, and other regions, suggesting that sustained high levels of GHB are genuinely neurotoxic over time.
Withdrawal and Rebound Excitability
With regular use, the brain adapts to the constant suppression of excitatory signaling by becoming more sensitive to stimulation. When GHB is suddenly removed, that heightened sensitivity is unmasked all at once. The result is a withdrawal syndrome that can include tremor, rapid heart rate, insomnia, anxiety, high blood pressure, delirium, seizures, and in severe cases, coma or death.
Because the core problem is the sudden loss of GABA-B activation, standard sedatives like benzodiazepines (which work on GABA-A receptors) often have limited effectiveness. Clinical experience has shown that adding a GABA-B agonist like baclofen, which directly replaces the missing receptor stimulation, can be critical for controlling withdrawal seizures that benzodiazepines alone cannot stop. This underscores how specifically GHB rewires the brain’s inhibitory balance: the withdrawal is not a generic sedative rebound but a GABA-B-specific crisis.
How the Body Clears GHB
GHB is metabolized quickly. The body converts it first to succinic semialdehyde, then to succinic acid, which enters the normal energy-production cycle in cells. The elimination half-life in healthy adults is approximately 36 to 40 minutes, meaning most of a dose is cleared within a few hours. This rapid metabolism is one reason GHB is difficult to detect in drug screening and why its effects, while intense, are relatively short-lived compared to other sedatives. It also means that redosing carries serious risk: because the subjective effects fade before all the drug is gone, someone who takes a second dose too soon can push blood levels into a dangerous range.